SCHWIND appoints new head of global marketing solutions

News
Article

Lohith Shetty will lead marketing for the company, based in Kleinostheim, Germany

Lohith Shetty. Image courtesy of SCHWIND

Lohith Shetty. Image courtesy of SCHWIND

On Wednesday, SCHWIND eye-tech-solutions GmbH announced Lohith Shetty will join the ophthalmic technology company, based in Kleinostheim, Germany, as the new head of global marketing solutions. Shetty brings more than 13 years of experience in healthcare technology1 to the role; most recently, he served as a marketing manager for global strategic marketing and clinical content at ZEISS Medical Technology.

In a press release, SCHWIND described the role, putting an emphasis on Shetty’s client collaboration and opportunities for building relationships with SCHWIND technology’s end users. Additionally, in the global marketing role, Shetty will focus heavily on international distribution and making SCHWIND technologies more accessible worldwide. SCHWIND is a manufacturer of both diagnostic tools and treatment systems for ophthalmic conditions. The femtosecond laser SCHWIND ATOS and excimer laser SCHWIND AMARIS round out the refractive portfolio, while the SCHWIND MS-39, SIRIUS+ and PERAMIS provide imaging options for the anterior segment.

Domenic Von Planta, CEO of SCHWIND, said that Shetty’s appointment comes immediately following a major milestone for the company: production of its 100th SCHWIND ATOS femtosecond laser. “This is a testimony to the fact that we are well positioned for great growth in following years,” Von Planta said. He stated that the expansion to the leadership team comes at the perfect time to help meet SCHWIND’s production goals. “With onboarding of Lohith Shetty, we further reinforce our marketing efforts to achieve our ambitious vision,” Planta said.1

SCHWIND’s chief sales officer Lars Ederleh, who was appointed in summer 2023, also commented on Shetty’s expertise. “Lohith Shetty offers both specialist know-how and an understanding of the future requirements of our market,” Ederleh said. “His experience and expertise in the refractive segment are a major value add to our team. We look forward to working with him to further extend our global market position and increase demand for SCHWIND technologies in our target markets.”

Reference
  1. SCHWIND. New Head of Marketing at SCHWIND eye-tech-solutions. Published 17 April 2024. Accessed 17 April 2024.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
Related Content
© 2025 MJH Life Sciences

All rights reserved.